Literature DB >> 12352147

Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy.

Rochelle P Walensky1, Sue J Goldie, Paul E Sax, Milton C Weinstein, A David Paltiel, April D Kimmel, George R Seage, Elena Losina, Hong Zhang, Runa Islam, Kenneth A Freedberg.   

Abstract

With limited data available on the optimal treatment of primary HIV infection, disease modeling can be used to project clinical outcomes and inform decision makers. The authors developed a simulation model to evaluate the clinical outcomes and life expectancy projections for three primary HIV infection treatment strategies: 1) continuous antiretroviral therapy (ART) initiated at CD4 count <350 cells/mm(3); 2) continuous ART initiated immediately on diagnosis of primary HIV infection; and 3) ART initiated on diagnosis followed by structured treatment interruption. Projected life expectancies for the three strategies were 23.92, 24.46, and 26.07 years, respectively. The impact of key variables was assessed in sensitivity analysis, with the structured treatment interruption strategy remaining the most effective over a broad range of inputs. The immunologic benefit associated with immediate therapy and the potential for antiretroviral resistance due to structured treatment interruption have the most important impact on the optimal strategy. Based on current data, immediate treatment on diagnosis of primary HIV infection followed by structured treatment interruption will likely yield the best outcome. These results can assist decision makers and those planning clinical trials in defining evidence-based performance measures for primary HIV infection treatment and future trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352147     DOI: 10.1097/00126334-200209010-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  9 in total

1.  Projected survival gains from revising state laws requiring written opt-in consent for HIV testing.

Authors:  Michael D April; John J Chiosi; A David Paltiel; Paul E Sax; Rochelle P Walensky
Journal:  J Gen Intern Med       Date:  2011-02-01       Impact factor: 5.128

2.  Costs versus benefits: best possible and best practical treatment regimens for HIV.

Authors:  O Krakovska; L M Wahl
Journal:  J Math Biol       Date:  2007-01-05       Impact factor: 2.259

3.  Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC.

Authors:  Rochelle P Walensky; A David Paltiel; Elena Losina; Bethany L Morris; Callie A Scott; Erin R Rhode; George R Seage; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

4.  Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis.

Authors:  Erika G Martin; A David Paltiel; Rochelle P Walensky; Bruce R Schackman
Journal:  Value Health       Date:  2010-10-15       Impact factor: 5.725

5.  A case of multiorgan failure following interruption of antiretroviral treatment.

Authors:  M Crespo; J C Paradiñeiro; E Ribera; I Ruiz; V Falcó; J Lopez-Quiñones; I Ocaña; A Pahissa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-12-11       Impact factor: 3.267

6.  Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.

Authors:  Elena Losina; Bruce R Schackman; Sara N Sadownik; Kelly A Gebo; Rochelle P Walensky; John J Chiosi; Milton C Weinstein; Perrin L Hicks; Wendy H Aaronson; Richard D Moore; A David Paltiel; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

7.  Scaling up antiretroviral therapy in South Africa: the impact of speed on survival.

Authors:  Rochelle P Walensky; Robin Wood; Milton C Weinstein; Neil A Martinson; Elena Losina; Mariam O Fofana; Sue J Goldie; Nomita Divi; Yazdan Yazdanpanah; Bingxia Wang; A David Paltiel; Kenneth A Freedberg
Journal:  J Infect Dis       Date:  2008-05-01       Impact factor: 5.226

8.  Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.

Authors:  R Scott Braithwaite; Mark S Roberts; Chung Chou H Chang; Matthew Bidwell Goetz; Cynthia L Gibert; Maria C Rodriguez-Barradas; Steven Shechter; Andrew Schaefer; Kimberly Nucifora; Robert Koppenhaver; Amy C Justice
Journal:  Ann Intern Med       Date:  2008-02-05       Impact factor: 25.391

9.  Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India.

Authors:  Kartik K Venkatesh; Jessica E Becker; Nagalingeswaran Kumarasamy; Yoriko M Nakamura; Kenneth H Mayer; Elena Losina; Soumya Swaminathan; Timothy P Flanigan; Rochelle P Walensky; Kenneth A Freedberg
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.